Softwr

Healthcare · head to head

Paige vs Phreesia

Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite
Phreesia logo

Phreesia

Healthcare

Patient intake, registration and payments platform for medical practices

From
Free
Rated
-
Full reviewWebsite

The short version

  • Only Phreesia has a free tier, so it costs nothing to try first.
  • Each has a real cost: Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.; Phreesia no price is published: the vendor states pricing is customised to organisation size, workflows and products used, and is given only as a tailored quote
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Paige and Phreesia actually diverge.

Attributes where Paige and Phreesia differ
AttributePaigePhreesia
Starting priceOn requestFree
Pricing modelquotesubscription
Free tierNoYes
PlatformsWeb, Cloud, On-premiseWeb

Identical on both: user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

Only in Phreesia

Nothing recorded that Paige does not also cover.

What people use each for

The jobs each tool is most often brought in to do.

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Phreesia
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Phreesia
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Phreesia
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Phreesia

Phreesia

  • Digital patient intake and registration ahead of an appointmentnot Paige
  • Collecting patient payments as part of the intake workflownot Paige
  • Automating clinical screening questionnaires at check-innot Paige

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Phreesia

  • No price is published: the vendor states pricing is customised to organisation size, workflows and products used, and is given only as a tailored quote
  • The current free access to the Intake platform is time limited and ends on 31 December 2026, with the rate that follows undisclosed
  • A buyer must book a demo before receiving any figure

Pricing, plan by plan

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Phreesia

Free

No published plan breakdown. See the Phreesia review.

Which should you pick?

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Choose Phreesia if

  • You want to start without paying.
Phreesia review

Questions people ask

Is Paige or Phreesia better?
Neither clearly leads. Paige starts at On request and Phreesia at Free, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Paige or Phreesia?
Phreesia has a free tier; the other does not. Paid plans start at On request for Paige and Free for Phreesia.
Does Paige or Phreesia run on more platforms?
Paige runs on Web, Cloud, On-premise. Phreesia runs on Web.
Can I use Phreesia for free?
Yes. Phreesia has a free tier, so you can try it without paying. Paige starts at On request.
What is Paige best used for?
Paige is most often used for a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable, a pathology department already digitised that wants a documented safety net against missed small foci of cancer, a hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reporting, a pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variability. Of those, a reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffable and a pathology department already digitised that wants a documented safety net against missed small foci of cancer are not what Phreesia is typically brought in for.
What can Paige do that Phreesia cannot?
Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Phreesia: Is there a free version of Phreesia?

Phreesia offers free access to the complete Phreesia Intake platform through December 31, 2026. Standard subscription pricing begins January 1, 2027, with transparent pricing and no per-message charges or hidden fees.

Source
Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Phreesia: How is Phreesia priced?

Phreesia pricing is customized based on organization size, workflows, and products used. The company offers transparent subscription pricing with no per-message charges. Specific pricing requires contacting the company via their demo request form for a tailored quote.

Source
Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Paige

More on Phreesia

Keep looking

Other head to heads